These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36678723)
1. Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials. Monteleone G; Stolfi C Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678723 [TBL] [Abstract][Full Text] [Related]
2. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate? Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457 [TBL] [Abstract][Full Text] [Related]
3. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease. Ardizzone S; Bevivino G; Monteleone G Therap Adv Gastroenterol; 2016 Jul; 9(4):527-32. PubMed ID: 27366221 [TBL] [Abstract][Full Text] [Related]
4. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases. Laudisi F; Dinallo V; Di Fusco D; Monteleone G Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974 [TBL] [Abstract][Full Text] [Related]
5. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968 [TBL] [Abstract][Full Text] [Related]
6. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide. Marafini I; Monteleone I; Dinallo V; Di Fusco D; De Simone V; Laudisi F; Fantini MC; Di Sabatino A; Pallone F; Monteleone G J Crohns Colitis; 2017 May; 11(5):603-609. PubMed ID: 28453765 [TBL] [Abstract][Full Text] [Related]
7. TGF-Beta signaling manipulation as potential therapy for IBD. Marafini I; Zorzi F; Codazza S; Pallone F; Monteleone G Curr Drug Targets; 2013 Nov; 14(12):1400-4. PubMed ID: 23489130 [TBL] [Abstract][Full Text] [Related]
8. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. Marafini I; Stolfi C; Troncone E; Lolli E; Onali S; Paoluzi OA; Fantini MC; Biancone L; Calabrese E; Di Grazia A; Monteleone I; Lenti MV; Di Sabatino A; Monteleone G BioDrugs; 2021 May; 35(3):325-336. PubMed ID: 33871807 [TBL] [Abstract][Full Text] [Related]
9. Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice. Izzo R; Bevivino G; De Simone V; Sedda S; Monteleone I; Marafini I; Di Giovangiulio M; Rizzo A; Franzè E; Colantoni A; Ortenzi A; Monteleone G Inflamm Bowel Dis; 2018 May; 24(6):1213-1224. PubMed ID: 29668937 [TBL] [Abstract][Full Text] [Related]
10. Role of Smad7 in inflammatory bowel diseases. Monteleone G; Caruso R; Pallone F World J Gastroenterol; 2012 Oct; 18(40):5664-8. PubMed ID: 23155305 [TBL] [Abstract][Full Text] [Related]
11. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Marafini I; Troncone E; Salvatori S; Monteleone G Pharmacol Res; 2020 May; 155():104757. PubMed ID: 32194176 [TBL] [Abstract][Full Text] [Related]